Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atopic dermatitis: recent therapeutic advances.

Y de Prost1

  • 1Hôpital Necker, Paris, France.

Pediatric Dermatology
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

New treatments for severe atopic dermatitis (AD) target the immune system. While effective in the short term, these therapies like oral cyclosporine and gamma-interferon offer temporary relief for AD flares.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphomatoid papulosis in children: a series of 25 cases.

The British journal of dermatology·2014
Same author

[Breastfeeding and atopic dermatitis].

Annales de dermatologie et de venereologie·2012
Same author

Nutritional outcome in children with severe generalized recessive dystrophic epidermolysis bullosa: a short- and long-term evaluation of gastrostomy and enteral feeding.

The British journal of dermatology·2011
Same author

Germline mosaicism in keratitis-ichthyosis-deafness syndrome: pre-natal diagnosis in a familial lethal form.

Clinical genetics·2010
Same author

Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2009
Same author

Neonatal cases of infantile myofibromatosis do not derive from maternal cells transferred during pregnancy.

The British journal of dermatology·2009

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Severe atopic dermatitis (AD) is a chronic inflammatory skin condition.
  • Current management strategies often involve targeting the immune system.
  • Understanding immune pathways is crucial for developing effective AD treatments.

Purpose of the Study:

  • To review recently proposed immunomodulatory treatments for severe atopic dermatitis.
  • To evaluate the mechanisms of action and efficacy of these novel therapies.
  • To discuss the limitations and transient effects of current treatments.

Main Methods:

  • Review of recent scientific literature on atopic dermatitis treatments.
  • Analysis of the immunological mechanisms targeted by new therapies.

Related Experiment Videos

  • Assessment of clinical outcomes and side effect profiles.

    • Main Results:

    • Oral cyclosporine modulates CD4+ cells, interleukins, and Langerhans cells but has significant side effects and relapse potential.
    • Thymic hormone extracts address cellular immunity deficits in severe AD.
    • Gamma-interferon inhibits IgE synthesis and enhances monocyte function.
    • Allergen-specific antibody complexes and interleukin-2 are newer modalities with temporary effects.

    Conclusions:

    • Several immunomodulatory treatments show promise for severe AD flares.
    • Most current treatments provide only transitory relief.
    • The risk of side effects and disease recurrence limits the long-term utility of some therapies like oral cyclosporine.